Tech Company Financing Transactions
Vaxxas Funding Round
Vaxxas secured a $23 million financing round on 12/5/2022. Investors included OneVentures and Uniquest of Korea.
Transaction Overview
Company Name
Announced On
12/5/2022
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Undisclosed
Investors
OneVentures (Lead Investor)
Uniquest of Korea (Lead Investor)
Proceeds Purpose
The company intends to use the funds to accelerate the clinical program for its COVID-19 vaccine patch candidate, which is currently in Phase I clinical trials.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
47 Thorndike St. B1-1
Cambridge, MA 02141
USA
Cambridge, MA 02141
USA
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Vaxxas is focussed on enhancing the performance of existing and next generation vaccines through the development and commercialization of the company's novel vaccine delivery technology - the Nanopatch.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Hoey
Chief Operating Officer
Angus Forster
VP - Engineering
Michael Junger
VP - Operations
Charles Ross
Browse more venture capital transactions:
Prev: 12/5/2022: smoodi venture capital transaction
Next: 12/5/2022: Apromore venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs